RNA Based Therapeutics And Vaccines Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (RNA-based Therapeutics, RNA-based Vaccines), By Indication (Oncology, Ophthalmic Disorders, Immunology, Cardiovascular Disorders, Infectious Diseases, Genetic Disorders, CNS Disorders, Others), By Type (siRNA, ASO, mRNA, saRNA, miRNA, tRNA, Aptamers, Others) and Region Forecast 2020-2031

RNA Based Therapeutics and Vaccines Market size was valued at US$ 63,626 million in 2024 and is expected to reach US$ 82,606 million by 2031, growing at a significant CAGR of 3.8% from 2025-2031. The market is likely to experience a steep rise in its growth during the forecast period due to the rise in the prevalence of chronic diseases such as diabetes, tuberculosis, cancer, and certain other cardiovascular conditions. RNA therapeutics and vaccines hold the distinction of providing better stability as compared to their counterparts. Though the majority of them are under trials (as mentioned above), they are increasingly preferred when it comes to treating obstinate disorders. Rapid advancement in technologies particularly in the healthcare sector has significantly lifted the demand for RNA-based therapeutics and vaccines. 

The healthcare sector has been bringing their minds together to bring stability to the RNA molecules in the body with limited bioavailability. It is the RNA therapeutics that when combined with protein/ lipid nanoparticles provide better stability. Despite being in a clinical research phase the RNA therapeutics has been extensively explored with a primary aim to treat difficult diseases. One of the major factors that is driving the market is the rise of promising technologies such as antisense technology, smart technology, and RNAi interference technology. The market primarily finds cures for cancer and infectious diseases and since the pool of patients is large, the demand for the market subsequently is also high. This creates a huge opportunity globally for market. The lack of alternative treatment options for rare diseases further boosted the growth of RNA-based therapeutics and vaccines during the forecast period. Aiding the growth of this market, the increasing focus of legislative bodies on developing reimbursement policies has fueled the development process of RNA molecules.

Key Developments:

• In Jan 2022, Novartis and Alnylam have agreed to collaborate on the discovery and development of siRNA-based targeted therapy to restore functional liver cells in patients with end-stage liver disease. The agreement will bring Alnylam proprietary siRNA technology to bear on liver target identified by Novartis researchers.
• In April 2020, Blackstone and Alnylam Entered Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics